SCHEMBL4355071

SCHEMBL4355071

CCOc1ccc(F)cc1C(=O)c1cnc([S+](C)[O-])nc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 5/20 0.42
CDK4 P11802 5/20 0.42
CCND1 P24385 5/20 0.42
CDK2 P24941 5/20 0.42
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MRGPRX1 Q96LB2 4/20 0.37
CHRNA7 P36544 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
CSNK1D P48730 1/20 0.35
TSPO P30536 1/20 0.34
CREBBP Q92793 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
LCLAT1 Q6UWP7 1/20 0.34
HRH4 Q9H3N8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359313 0.92 CDK1 (0.41) CDK1CDK4CCND1CDK2NPC1
SCHEMBL4350221 0.90 CDK1 (0.52) CDK1CDK4CCND1CDK2CHRNA7
SCHEMBL4347552 0.87 CDK4 (0.36) CDK1CDK4CCND1CDK2NPC1
SCHEMBL4354997 0.83 CDK1 (0.49) CDK1CDK4CCND1CDK2HSD17B10
SCHEMBL4354299 0.81 MAPK1 (0.45) CDK1CDK4CCND1CDK2NPC1
SCHEMBL4352080 0.81 CDK1 (0.40) CDK1CDK4CCND1CDK2RAB9A
SCHEMBL13621484 0.80 SMN1; SMN2 (0.44) CDK1CDK4CCND1CDK2NPC1
SCHEMBL4358951 0.77 CDK4 (0.35) CDK1CDK4CCND1CDK2NPC1
SCHEMBL4346982 0.77 CDK4 (0.35) CDK1CDK4CCND1CDK2NPC1
SCHEMBL13621474 0.77 CDK1 (0.49) CDK1CDK4CCND1CDK2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US claimed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.